Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

被引：3
|
作者：
Bersanelli, Melissa [1 ]
Gnetti, Letizia [2 ]
Azzoni, Cinzia [2 ]
Bottarelli, Lorena [2 ]
Sverzellati, Nicola [3 ]
Campanini, Nicoletta [2 ]
Varotti, Elena [2 ]
Corrado, Michele [3 ]
Parziale, Raffaele [3 ]
Rapacchi, Elena [1 ]
Caruso, Giuseppe [1 ]
Leonardi, Francesco [1 ]
Silini, Enrico Maria [2 ]
Buti, Sebastiano [1 ]
机构：
[1] Univ Hosp Parma, Med Oncol, Via Gramsci 14, I-43126 Parma, Italy
[2] Univ Hosp Parma, Pathol Anat Unit, Via Gramsci 14, I-43126 Parma, Italy
[3] Univ Hosp Parma, Radiol Unit, Via Gramsci 14, I-43126 Parma, Italy
来源：
IMMUNOTHERAPY | 2018年 / 10卷 / 09期
关键词：
FHIT; loss of heterozygosity; renal cell carcinoma; SPORADIC BREAST-CANCER; CLEAR-CELL CARCINOMA; MISMATCH-REPAIR; MICROSATELLITE INSTABILITY; OVARIAN-CANCER; BRCA2; VHL; 3P; TUMORIGENESIS; GUIDELINES;
D O I：
10.2217/imt-2017-0160
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.
引用
收藏
页码：743 / +
页数：11
相关论文
共 50 条
  • [41] ROLE OF PRIMARY TUMOR IN ADVANCED RENAL CELL CARCINOMA (RCC) PATIENTS TREATED WITH NIVOLUMAB/IPILIMMUMAB OR CABOZANTINIB
    Ciccarese, Chiara
    Maruzzo, Marco
    Atzori, Francesco
    Galli, Luca
    Scagliarini, Sarah
    Massari, Francesco
    Verzoni, Elena
    Cannella, Maria Antonella
    Maratta, Maria Grazia
    Astore, Serena
    Caserta, Claudia
    Bimabatti, Davide
    Deppieri, Filippo Maria
    Dessi, Mariele
    Paolieri, Federico
    Riccardi, Ferdinando
    Bracarda, Sergio
    De Giorgi, Ugo
    Basso, Umberto
    Procopio, Giuseppe
    Tortora, Giampaolo
    ANTICANCER RESEARCH, 2021, 41 (10) : 5309 - 5312
  • [42] Somatic mutations and loss of heterozygosity of the VHL tumor suppressor gene in unclassified renal cell carcinomas
    Chiesa, A
    Sobel, M
    Bryant, B
    Panizo, A
    Linehan, WM
    Merino, MJ
    LABORATORY INVESTIGATION, 2001, 81 (01) : 105A - 105A
  • [43] Rare loss of heterozygosity of the MTS1 and MTS2 tumor suppressor genes in differentiated human thyroid cancer
    Schulte, KM
    Staudt, S
    Niederacher, D
    Finken-Eigen, M
    Köhrer, K
    Goretzki, PE
    Röher, HD
    HORMONE AND METABOLIC RESEARCH, 1998, 30 (09) : 549 - 554
  • [44] Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
    Shao, Ning
    Wan, Fangning
    Zhu, Yao
    Ye, Dingwei
    MEDICAL SCIENCE MONITOR, 2019, 25 : 6518 - 6522
  • [45] Loss of heterozygosity studies indicate that chromosome arm Ip harbors a tumor suppressor gene for renal oncocytomas
    ThrashBingham, CA
    Salazar, H
    Greenberg, RE
    Tartof, KD
    GENES CHROMOSOMES & CANCER, 1996, 16 (01): : 64 - 67
  • [46] Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer
    Friedrich, MG
    Erbersdobler, A
    Schwaibold, H
    Conrad, S
    Huland, E
    Huland, H
    JOURNAL OF UROLOGY, 2000, 163 (03): : 1039 - 1042
  • [47] TUMOR SUPPRESSOR GENES AND CANCER
    MAY, P
    PATHOLOGIE BIOLOGIE, 1991, 39 (09): : 864 - 864
  • [48] PTEN, a putative prostate tumor suppressor gene: Loss of heterozygosity in localized prostate cancer.
    Rubin, MA
    Reid, KA
    Wang, SL
    Lequesne, E
    Olsson, CA
    Parsons, R
    MODERN PATHOLOGY, 1998, 11 (01) : 94A - 94A
  • [49] Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence (vol 14, pg 65, 2002)
    Thiagalingam, S
    Foy, RL
    Cheng, KH
    Lee, HJ
    Thiagalingam, A
    Ponte, JF
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (03) : 374 - 374
  • [50] The optimal rate of chromosome loss for the inactivation of tumor suppressor genes in cancer
    Komarova, NL
    Wodarz, D
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (18) : 7017 - 7021
12345